Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Start Date01 Aug 2024

Sponsor / Collaborator

The General Hospital Corp.

[+1]

CTR20241005 / RecruitingNot Applicable

头孢克洛干混悬剂在健康试验参与者中的随机、开放、单次给药、两制剂、两周期人体生物等效性研究

[Translation] A randomized, open-label, single-dose, two-formulation, two-period human bioequivalence study of cefaclor dry suspension in healthy trial participants

主要研究目的：以江苏正大清江制药有限公司研制的头孢克洛干混悬剂（规格：0.125g）为受试制剂，按生物等效性研究的有关规定，与苏州西克罗制药有限公司生产的头孢克洛干混悬剂（商品名：希刻劳®，参比制剂，规格：0.125g）对比在健康人体内的相对生物利用度，考察两制剂的人体生物等效性。次要研究目的：比较头孢克洛干混悬剂受试制剂（规格：0.125g）和参比制剂（规格：0.125g）在健康试验参与者中的安全性。

[Translation]

Main research purpose: The cefaclor dry suspension (specification: 0.125g) developed by Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. was used as the test preparation. According to the relevant provisions of bioequivalence studies, the relative bioavailability of the two preparations in healthy humans was compared with that of the cefaclor dry suspension (trade name: Xikeluo®, reference preparation, specification: 0.125g) produced by Suzhou Xikro Pharmaceutical Co., Ltd. to investigate the human bioequivalence of the two preparations. Secondary research purpose: Compare the safety of the cefaclor dry suspension test preparation (specification: 0.125g) and the reference preparation (specification: 0.125g) in healthy trial participants.

Start Date18 Apr 2024

Sponsor / Collaborator

Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd.

CTR20233818 / RecruitingNot Applicable

头孢克洛缓释片在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹/餐后状态下的生物等效性试验

[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of cefaclor sustained-release tablets in healthy subjects under fasting/fed conditions

健康受试者空腹/餐后状态下，口服单剂量头孢克洛缓释片（受试制剂T，广州白云山医药集团股份有限公司白云山制药总厂生产，规格：0.375g/片）与头孢克洛缓释片（Ⅱ）（参比制剂R，苏州西克罗制药有限公司生产，商品名：希刻劳®，规格：0.375g/片）后，考察空腹和餐后条件下受试制剂与参比制剂的吸收速度和吸收程度，评价受试制剂与参比制剂是否具有生物等效性。

[Translation]

Healthy subjects were given a single oral dose of cefaclor sustained-release tablets (test preparation T, produced by Baiyunshan Pharmaceutical Factory of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., specification: 0.375 g/tablet) and cefaclor sustained-release tablets (II) (reference preparation R, produced by Suzhou Xikro Pharmaceutical Co., Ltd., trade name: Xikro®, specification: 0.375 g/tablet) in the fasting/postprandial state. The absorption rate and extent of the test preparation and the reference preparation under fasting and postprandial conditions were investigated to evaluate whether the test preparation and the reference preparation were bioequivalent.

Start Date03 Jan 2024

Sponsor / Collaborator

Guangzhou Baiyunshan General Pharmaceutical Factory

100 Clinical Results associated with Cefaclor

100 Translational Medicine associated with Cefaclor

100 Patents (Medical) associated with Cefaclor

1,853

Literatures (Medical) associated with Cefaclor

01 May 2024·Environmental research

Activated carbon fiber as an efficient co-catalyst toward accelerating Fe2+/Fe3+ cycling for improved removal of antibiotic cefaclor via electro-Fenton process using a gas diffusion electrode

Article

Author: Wang, Aimin ; Zhang, Zhongguo ; Ren, Songyu ; Song, Yongjun ; Zhang, Ni ; Zhang, Yanyu ; Zhao, Yue

The electro-Fenton (EF) based on gas-diffusion electrodes (GDEs) reveals promising application prospective towards recalcitrant organics degradation because such GDEs often yields superior H₂O₂ generation efficiency and selectivity. However, the low efficiency of Fe²⁺/Fe³⁺ cycle with GDEs is always considered to be the limiting step for the EF process. In this study, activated carbon fiber (ACF) was firstly employed as co-catalyst to facilitate the performance of antibiotic cefaclor (CEC) decomposition in EF process. It was found that the addition of ACF co-catalyst achieved a rapid Fe²⁺/Fe³⁺ cycling, which significantly enhanced Fenton's reaction and hydroxyl radicals (^•OH) generation. X-ray photoelectron spectroscopy (XPS) results indicated that the functional groups on ACF surface are related to the conversion of Fe³⁺ into Fe²⁺. Moreover, DMSO probing experiment confirmed the enhanced ^•OH production in EF + ACF system compared to conventional EF system. When inactive BDD and Ti₄O₇/Ti anodes were paired to EF system, the addition of ACF could significantly improve mineralization degree. However, a large amount of toxic byproducts, including chlorate (ClO₃^-) and perchlorate (ClO₄^-), were generated in these EF processes, especially for BDD anode, due to their robust oxidation capacity. Higher mineralization efficiency and less toxic ClO₄^- generation were obtained in the EF + ACF process with Ti₄O₇/Ti anode. This presents a novel alternative for efficient chloride-containing organic removal during wastewater remediation.

01 Dec 2023·Environmental research

Insights into antibiotic cefaclor mineralization by electro-Fenton and photoelectro-Fenton processes using a Ti/Ti4O7 anode: Performance, mechanism, and toxic chlorate/perchlorate formation

Article

Author: Ren, Songyu ; Wen, Zhenjun ; Zhang, Zhongguo ; Shao, Chaoran ; Wang, Aimin ; Zhang, Yanyu

A comparative degradation of antibiotic cefaclor (CEC) between Ti/Ti₄O₇ and Ti/RuO₂ anodes, in terms of degradation kinetics, mineralization efficiency, and formation of toxic chlorate (ClO₃^-) and perchlorate (ClO₄^-), was performed with electrochemical-oxidation (EO), electro-Fenton (EF), and photoelectro-Fenton (PEF) processes. Besides, CEC degradation by EF with boron-doped diamond (BDD) anode was also tested. Results showed CEC decays always followed pseudo-first-order kinetics, with increasing apparent rate constants in the sequence of EO < EF < PEF. The mineralization efficiency of the processes with Ti/Ti₄O₇ anode was higher than that of Ti/RuO₂ anode, but slightly lower than that of BDD anode. Under the optimal conditions, 94.8% mineralization was obtained in Ti/Ti₄O₇-PEF, which was much higher than 64.4% in Ti/RuO₂-PEF. The use of Ti/RuO₂ gave no generation of ClO₃^- or ClO₄^-, while the use of Ti/Ti₄O₇ yielded a small amount of ClO₃^- and trace amounts of ClO₄^-. Conversely, the use of BDD led to the highest generation of ClO₃^- and ClO₄^-. The reaction mechanism was studied systematically by detecting the generated H₂O₂ and ^•OH. The initial N of CEC was released as NH₄⁺ and, in smaller proportion, as NO₃^-. Four short-chain carboxylic acids and nine aromatic intermediates were also detected, a possible reaction sequence for CEC mineralization was finally proposed.

11 Oct 2023·Veterinary sciences

The Use of Additives to Prevent Urolithiasis in Lambs Fed Diets with a High Proportion of Concentrate.

Article

Author: Ramírez-Zamudio, Germán Darío ; Strefezzi, Ricardo de Francisco ; Cônsolo, Nara Regina Brandão ; Leme, Paulo Roberto ; Silva, Saulo Luz ; Bezerra, Helena Viel Alves ; Silva, Natália Marques da ; Buarque, Vicente Luiz Macêdo ; Rissi, Guilherme Pegoraro ; Gallo, Sarita Bonagurio ; Oliveira, Regner Ítalo Gonçalves de

This study aimed to evaluate the effectiveness of different additives in preventing urolithiasis in lambs fed a diet rich in concentrate and their impact on performance and blood and urinary parameters. Thirty-two noncastrated male lambs, crossbred Dorper × Santa Inês, with initial body weights (BWs) of 23 ± 0.1 kg and ages of 50 ± 5 days, were kept in individual pens and fed a diet composed of 6% Cynodon ssp. hay and 94% concentrate and subjected to four treatments: CON without inclusion of additives, addition of ACL 5 g/kg of dry matter (DM), addition of CCL 6.3 g/kg of DM, and addition of BZA 5 g/kg of DM. There was no effect of treatment or interaction with time on blood parameters (p > 0.050), and performance characteristics, morphometry of ruminal papillae, and scores of cecum and rumen lesions were not affected by the addition of additives to the diet (p > 0.050). Greater urinary acidification was observed in animals from CCL and ACL treatments (p = 0.033). Calcium chloride acidified the urinary pH and can be used instead of ammonium chloride at a concentration of 0.63% based on DM, when this is the objective.

News (Medical) associated with Cefaclor

15 Dec 2022

·www.prnewswire.com

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022. Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years. Out of concern about the spread of the epidemic, people began to hoard many related drugs. The Chinese government has issued the Catalogue to guide people to take drugs accordingly. A series of drugs of our Company are listed in the catalog, and the demand is huge. Our modern Traditional Chinese Medicine (TCM) anti-virus product: Andrographolide has been listed in the Catalogue Our cold medicine: Naproxen Sodium and Pseudoephedrine Hydrochloride Sustained Release Tablets (brand name, Pusen OK), in which the compound ingredient pseudoephedrine is in line with the cold symptom relief medicine recommended in the Catalog It was announced in many places in China in recent days that pharmacies will no longer register or upload customer information on "four types of drugs", which includes anti-fever, cough, antiviral and antibiotic drugs. This will benefit the sales of our main products, roxithromycin and cefaclor The market demand for our masks has also increased significantly Ms. Li Zhilin, CEO of China Pharma said: " With the liberalization of epidemic risk control measures across China, the number of infected people may rise rapidly. The public's need in keeping certain epidemic prevention materials and related drugs has been dramatically increasing. As a professional pharmaceutical manufacturer for nearly 30 years, we will continue to spare no effort to provide high-quality products to protect people's health." About China Pharma Holdings, Inc. China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit . The Company routinely posts important information on its website. Safe Harbor Statement Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation. SOURCE China Pharma Holdings, Inc.

06 Sep 2017

·www.bioportfolio.com

Yungjin Pharm Co Ltd 003520 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

Summary Yungjin Pharm Co Ltd Yungjin, a subsidiary of KTG Corp is a pharmaceutical company that develops, manufactures and distributes active pharmaceutical ingredients, formulations and tonic drinks. The company's API products include cephalosporins and other general products. It also provides cefaclor cap and dry syr, cefadroxil monohydrate, cefalexin monohydrate, cefamandole inj, cefcapene pivoxil tab and fine gran, cefmetazole inj, cefminox inj, cefotaxime inj, and cefatrizine propylene glycolate, among others. Yungjin offers formulation products for various therapeutic areas such as antibiotics, CNS, cardiovascular, endocrine system, respiratory, antiinflammatory and analgesics, antihistamine, antifungal, total nutrition, urinary system, vitamin and supplement, and cosmetics. The company also provides tonic drinks with pidotimod liquid. It operates through research and development institute, and factory located in Korea. Yungjin is headquartered in Seoul, South Korea. Yungjin Pharm Co Ltd 003520 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Cefaclor

External Link

KEGG	Wiki	ATC	Drug Bank
D02352	Cefaclor	J01DC04	DB00833

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Bronchitis	JP	Kyowa Pharmaceutical Industry Co., Ltd.	28 Jun 1988
Lymphadenitis	JP	Kyowa Pharmaceutical Industry Co., Ltd.	28 Jun 1988
Pharyngolaryngitis	JP	Kyowa Pharmaceutical Industry Co., Ltd.	28 Jun 1988
Pyoderma	JP	Kyowa Pharmaceutical Industry Co., Ltd.	28 Jun 1988
Secondary infection	JP	Kyowa Pharmaceutical Industry Co., Ltd.	28 Jun 1988
Gram-Negative Bacterial Infections	US	Eli Lilly & Co.	04 Apr 1979
Gram-Positive Bacterial Infections	US	Eli Lilly & Co.	04 Apr 1979
Lower Respiratory Tract Infections	US	Eli Lilly & Co.	04 Apr 1979
Otitis Media	US	Eli Lilly & Co.	04 Apr 1979
Pharyngitis	US	Eli Lilly & Co.	04 Apr 1979
Skin and skin structure infections	US	Eli Lilly & Co.	04 Apr 1979
Tonsillitis	US	Eli Lilly & Co.	04 Apr 1979
Urinary Tract Infections	US	Eli Lilly & Co.	04 Apr 1979
Bacterial Infections	GB	Flynn Pharma Ltd.	21 Aug 1978

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis